Related Experiment Videos
Cefamandole: in vitro and clinical pharmacokinetics
Abstract:
Cefamandole has a broader spectrum and greater potency than the other cephalosporins. It includes Haemophilus influenzae, most strains of Enterobacter, and many strains of indole-positive Proteus and Bacteroides, with a lower minimal inhibitory concentration for Escherichia coli, Klebsiella, etc. Concentrations of drug in the serum after the parenteral injection of cefamandole exceed manyfold the minimal inhibitory concentrations of over 82% of the bacteria studied. Approximately 65 to 85% is excreted in a biologically active form in the urine. This antibiotic offers advantages of antibacterial effectiveness and at the same time retains the safety of penicillin G and cephalothin in animals.
Insights
Cefamandole demonstrates broad-spectrum antibacterial activity and high potency, exceeding minimal inhibitory concentrations for most tested bacteria. This cephalosporin antibiotic is safely excreted in urine, offering effective antibacterial action.
Area of Science:
- Pharmacology and Microbiology
- Antibiotic Research and Development
Background:
- Cefamandole represents a cephalosporin antibiotic with enhanced spectrum and potency compared to existing agents.
- Understanding the pharmacokinetic and pharmacodynamic properties of novel antibiotics is crucial for clinical application.
Purpose of the Study:
- To evaluate the antibacterial spectrum and potency of cefamandole.
- To assess cefamandole's pharmacokinetic profile, including serum concentrations and urinary excretion.
- To compare the safety and efficacy profile of cefamandole with established antibiotics.
Main Methods:
- Determination of minimal inhibitory concentrations (MICs) against a range of bacterial pathogens.
- Measurement of serum drug concentrations following parenteral administration.
- Assessment of the proportion of biologically active drug excreted in urine.
Main Results:
- Cefamandole exhibited broader spectrum and greater potency, effectively inhibiting key pathogens including Haemophilus influenzae, Enterobacter, Proteus, and Bacteroides species.
- Serum concentrations post-injection significantly exceeded MICs for over 82% of tested bacteria.
- 65-85% of cefamandole was recovered in urine in an active form, indicating favorable renal excretion.
Conclusions:
- Cefamandole offers significant advantages in antibacterial effectiveness against a wide array of pathogens.
- The drug demonstrates favorable pharmacokinetics with high serum concentrations and efficient urinary excretion.
- Cefamandole provides a promising safety profile, comparable to penicillin G and cephalothin in animal models.